| Nov 13 |
Alto Neuroscience GAAP EPS of -$0.62
|
| Nov 12 |
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Oct 26 |
Notable analyst calls this week: McDonald's, Apple and Enphase Energy among top picks
|
| Oct 24 |
Wedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout
|
| Oct 23 |
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform
|
| Oct 23 |
Alto Neuroscience stock crashes amid failed study and Wedbush downgrade
|
| Oct 23 |
Alto hits new low as depression drug flunks key test
|
| Oct 23 |
Alto’s Phase IIb study of ALTO-100 for MDD fails to meet primary endpoint
|
| Oct 23 |
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
|
| Oct 22 |
Alto Neuroscience stock craters 57% post-market on failed study
|
